Our Pricing

Find Wegovy 1.7mg at the Cheapest Price Available

Searching for wegovy 1.7mg cheapest price uk options? At Cured Pharmacy, you'll find genuine UK-licensed Wegovy 1.7mg pens from £79.00, with transparent upfront pricing, free clinical consultation under 3 minutes, and 100% discreet packaging. Every prescription is assessed by our UK-registered clinical team, ensuring you receive safe, effective treatment at the lowest prices guaranteed in the UK.

Understanding Wegovy 1.7mg: The Third Dose in Your Weight Loss Journey

Wegovy 1.7mg represents the third dose escalation in the structured semaglutide treatment programme licensed by the MHRA for weight management. After starting at 0.25mg and progressing through 0.5mg and 1mg, patients typically reach the 1.7mg dose in their third month of treatment [1]. This gradual titration minimises gastrointestinal side effects whilst allowing your body to adapt to semaglutide's appetite-regulating mechanisms.

Semaglutide, the active ingredient in Wegovy, is a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1. At the 1.7mg dose, clinical trials demonstrated significant reductions in body weight, with participants continuing to lose weight as they progressed towards the maintenance dose of 2.4mg [2]. The STEP clinical trial programme showed that patients who completed the full dose escalation achieved an average of 15.3% body weight reduction over 68 weeks [2].

It's crucial to understand that Wegovy 1.7mg is not a standalone dose — it's part of a medically supervised escalation schedule. Your UK prescriber will confirm whether you're ready to progress from 1mg to 1.7mg based on your tolerance, side effect profile, and weight loss response. Skipping doses or starting at 1.7mg without prior titration increases the risk of severe nausea, vomiting, and treatment discontinuation.

Why Wegovy 1.7mg Cheapest Price UK Matters for Treatment Adherence

Weight loss treatment with Wegovy requires long-term commitment, typically spanning 12 months or more for optimal results. When patients face high medication costs, treatment adherence drops significantly — a pattern we've observed across thousands of consultations at Cured Pharmacy. By offering competitive UK pricing, we help ensure cost doesn't become a barrier to completing your full treatment course.

At Cured Pharmacy, Wegovy starts from £79.00 per pen, representing lower than typical market rates for genuine UK-licensed medication. Our transparent pricing model means you'll see the exact cost before your free consultation begins — no hidden fees, no surprise charges after your prescriber assessment. This upfront approach allows you to budget confidently for your entire treatment journey, from initial 0.25mg through to maintenance at 2.4mg.

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), has structured our pricing to reflect genuine cost savings without compromising on clinical safety or medication authenticity. Every Wegovy pen dispensed from our GPhC-registered pharmacy (9012511) is sourced directly from licensed UK wholesalers, complete with full patient information leaflets and temperature-controlled delivery.

What's Included in Your Wegovy 1.7mg Price

Your Wegovy prescription from Cured Pharmacy includes free online consultation with a UK-registered prescriber, discreet home delivery, ongoing clinical support, and access to our pharmacist team via phone (+44 116 4646009) throughout your treatment. Unlike some providers who charge separately for consultations or follow-up assessments, our pricing covers your complete care pathway from assessment through to prescription fulfilment.

How Wegovy 1.7mg Compares to Other Weight Loss Treatments

When evaluating weight loss options, UK patients often compare Wegovy (semaglutide) against other GLP-1 receptor agonists and combination therapies. Each medication has distinct mechanisms, dosing schedules, and clinical evidence supporting its use. Understanding these differences helps you and your prescriber select the most appropriate treatment for your individual circumstances.

Wegovy contains semaglutide, which activates GLP-1 receptors to reduce appetite and slow gastric emptying. Alternative injectable treatments work through similar or complementary pathways, but differ in their frequency of administration, dose escalation schedules, and magnitude of weight loss observed in clinical trials [3]. Some patients may respond better to one medication over another based on their metabolic profile, previous treatment history, and tolerance of side effects.

Your UK prescriber will consider multiple factors when recommending a specific treatment: your BMI, presence of weight-related comorbidities (such as type 2 diabetes or hypertension), previous weight loss attempts, and medication contraindications. At Cured Pharmacy, our clinical team has experience prescribing the full range of MHRA-licensed weight loss medications, ensuring you receive personalised advice rather than a one-size-fits-all approach.

Injectable vs Oral Weight Loss Medications

Injectable GLP-1 receptor agonists like Wegovy offer superior bioavailability compared to oral alternatives, as the medication bypasses first-pass hepatic metabolism. This allows for more consistent blood levels and typically greater weight loss outcomes. However, some patients prefer oral medications due to needle anxiety or lifestyle convenience. Your prescriber will discuss both options during your consultation, weighing clinical efficacy against your personal preferences and treatment goals.

Clinical Evidence Supporting Wegovy 1.7mg Efficacy

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme provides robust evidence for Wegovy's effectiveness across diverse patient populations. STEP 1, the largest trial involving 1,961 adults with obesity or overweight plus weight-related comorbidities, demonstrated that 83.5% of participants achieved at least 5% weight loss, with 66.1% achieving at least 10% reduction, and 48.0% reaching 15% or greater weight loss over 68 weeks [2].

Importantly, the dose escalation schedule used in STEP trials — the same protocol prescribed in UK clinical practice — showed that weight loss continued throughout the titration period. At the 1.7mg dose (typically administered during weeks 13-16), participants were still experiencing progressive weight reduction, with maximal effects observed after reaching the 2.4mg maintenance dose [2]. This underscores why completing the full escalation schedule is critical for optimal outcomes.

Beyond weight loss, STEP trials documented significant improvements in cardiometabolic risk factors. Participants experienced reductions in systolic blood pressure (average 6.2 mmHg decrease), improvements in lipid profiles, and better glycaemic control in those with prediabetes [4]. These benefits emerged progressively as patients moved through higher doses, including the 1.7mg stage, highlighting the medication's broader health impact beyond the number on the scale.

Managing Side Effects at the Wegovy 1.7mg Dose

As you progress to Wegovy 1.7mg, you may experience gastrointestinal side effects including nausea, diarrhoea, constipation, or abdominal discomfort. These effects are most common during the first few weeks after dose escalation and typically diminish as your body adapts to the higher semaglutide level [1]. In clinical trials, approximately 44% of participants reported nausea at some point during treatment, though severe cases requiring discontinuation were uncommon (4.3% of patients) [2].

Practical strategies can significantly reduce side effect severity at the 1.7mg dose. Eating smaller, more frequent meals rather than large portions helps minimise nausea. Avoiding high-fat, fried, or heavily spiced foods during the first two weeks after dose escalation reduces gastric distress. Staying well-hydrated and maintaining regular meal timing supports your digestive system's adaptation to semaglutide's effects on gastric emptying.

If you experience persistent or severe side effects at 1.7mg, contact your prescriber before your next scheduled injection. In some cases, remaining at the 1mg dose for an additional four weeks allows better tolerance before progressing. Never adjust your dose independently — changes to your Wegovy schedule must be supervised by a UK-registered prescriber who can assess your individual response and determine the safest path forward.

When to Seek Medical Advice

Seek immediate medical attention if you experience severe abdominal pain that doesn't resolve, persistent vomiting preventing fluid intake, signs of pancreatitis (severe upper abdominal pain radiating to your back), or symptoms of gallbladder problems (yellowing of skin or eyes, fever with abdominal pain). Whilst these serious side effects are rare, occurring in less than 2% of trial participants, prompt medical assessment is essential if they develop [2]. Our pharmacy team at Cured Pharmacy is available on (+44) 116 4646009 for non-emergency concerns about your Wegovy treatment.

Starting Your Wegovy 1.7mg Treatment with Cured Pharmacy

Beginning treatment at Cured Pharmacy starts with a free online consultation that takes under 3 minutes to complete. You'll answer questions about your medical history, current medications, weight loss goals, and any previous experience with GLP-1 treatments. This information allows our UK-registered prescribers to assess whether Wegovy is clinically appropriate for you and to confirm you're ready to progress to the 1.7mg dose if you're already on treatment.

If your prescriber approves Wegovy 1.7mg, your prescription is sent electronically to our GPhC-registered pharmacy (9012511) for dispensing. We source all Wegovy pens from licensed UK wholesalers, ensuring you receive genuine MHRA-approved medication with full product authentication. Your order is packaged discreetly — with no external markings indicating contents — and dispatched via temperature-controlled courier to maintain medication integrity throughout transit.

After receiving your Wegovy 1.7mg pens, you'll have ongoing access to our clinical support team. Whether you have questions about injection technique, side effect management, or when to progress to the next dose, our pharmacists are available by phone or through your online account. This continuity of care ensures you're never navigating your weight loss journey alone, with professional guidance available whenever you need it.

Eligibility Criteria for Wegovy 1.7mg

To be prescribed Wegovy in the UK, you must have a BMI of 30 kg/m² or above, or a BMI of 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea. If you're requesting the 1.7mg dose specifically, your prescriber will verify you've completed the earlier titration stages (0.25mg, 0.5mg, and 1mg) and tolerated them appropriately. Starting directly at 1.7mg without prior dose escalation is not clinically recommended and will not be approved by UK prescribers due to increased risk of severe adverse effects.

Scientific References

1. Novo Nordisk. (2023). Wegovy 1.7 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed by the MHRA for weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with weight-related comorbidities. Individual results may vary. Weight loss outcomes reported in clinical trials represent average responses and are not guaranteed for all patients. Side effects can occur — refer to the patient information leaflet or speak with your prescriber if you have concerns.